Regeneron (REGN) Announces Dupixent is Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Regeneron (REGN) Announces Dupixent is Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis

Sanofi (SNY) Reports Q3 EPS of EUR1.92

October 31, 2019 8:05 AM EDT

Sanofi (NASDAQ: SNY) reported Q3 EPS of EUR1.92. Revenue for the quarter came in at EUR9.5 billion versus the consensus estimate of EUR10.38 billion.

Third-quarter 2019 sales performance(3) led by Sanofi Genzyme and Emerging Markets

Net sales were 9,499 million, up 1.1% on a reported basis, down 1.1%(3) at CER and up 0.5% at CER/CS(4).Sanofi Genzyme sales increased 19.5% driven by continued strong uptake of Dupixent®.Vaccines sales decreased 9.8% reflecting anticipated weighting of U.S. flu vaccines supply towards fourth quarter.CHC sales up 0.4%, impacted by Zantac® voluntary... More